Liver function may change how this drug works
NCT ID NCT06336018
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study looks at how the drug etavopivat is handled by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. 48 adults received a single dose, and researchers measured drug levels in the blood over 7-9 days. The goal is to understand if liver impairment affects drug exposure, which could guide future dosing recommendations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amer. Rrsch Corp-TX Liver Inst
San Antonio, Texas, 78215, United States
-
Cure Clinical Research LLC
Orange, California, 92866, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32806, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Pinnacle Clinical Research
San Antonio, Texas, 78229, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
etavopivat
What this could lead to
If successful, this study could help doctors determine the right dose of etavopivat for people with liver problems, making the drug safer and more effective.
What could go wrong
This is an early-phase study with only a single dose, so results may not predict long-term effects. It is small and focused on drug processing, not on treating a disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.